PALO ALTO, Calif.--(BUSINESS WIRE)--Medable Inc., the industry-leading technology platform for patient-centered clinical trials, today announced a new patient-first oncology offering that enables life sciences companies to improve patient access, enrollment, and retention in cancer trials. Medable’s new offering is an end-to-end suite that includes pre-built and validated DCT applications such as Total Consent and Televisit, an extensive eCOA oncology library, and protocol design consulting – with a single point of entry for patients, sites and sponsors.
The complexity of oncology poses numerous challenges to running a successful clinical trial, especially as many oncology trials are designed around small, genetically defined subsets of cancers. Finding eligible patients is difficult, and enrolling patient populations that reflect the diversity of cancer demographics adds a further challenge. In fact, two-thirds of oncology trials fold prematurely due to low enrollment as less than 5% of adult cancer patients participate in clinical research even though nearly two million Americans are diagnosed with cancer yearly.
Medable’s patient-first oncology solution can help improve access to trials, diversity, and retention by enabling patients undergoing intensive cancer therapies to participate both remotely at home and on-site. It simplifies data collection for sites and sponsors while keeping patients comfortable and engaged. Timely notifications and reminders help ensure compliance, while Medable’s real-time reporting functionality enhances patient- and caregiver-friendly ePROs, making it easy to track and respond to emerging toxicity and tolerability signals. Tokenization also streamlines data collection post-trial for lifelong follow-up, connecting patient trial data and real-world data to capture critical endpoints.
“The reinvigorated Cancer Moonshot initiative coupled with the FDA’s emphasis on diversity in clinical research is driving an urgent need to improve access to cancer trials,” said Musaddiq Khan, vice president of Therapeutic Area Solutions at Medable. “Our DCT offering is designed around the core needs of oncology trials while enabling optionality to improve access and the patient experience. Meeting patients where they are while offering better insight and data to site and study teams improves the experience for everyone and, subsequently, retention.”
More than 22,000 cancer patients have been screened using Medable’s platform across 3,300 contracted sites and 60 countries. Medable customers have achieved impressive results – including 200 percent faster enrollment and 50 percent cost reductions. A new study from Tufts Center for the Study of Drug Development shows that decentralized trials can achieve net financial benefits ranging from five to 13 times for Phase II and III trials, equating to roughly $10 million ROI and $39 million ROI, respectively.
For more information about Medable’s new oncology offering, download this case study or visit https://www.medable.com/products/oncology.
About Medable
Medable is on a mission to get effective therapies to patients faster by transforming clinical drug development with disruptive technologies. The company’s digital platform streamlines design, recruitment, retention, and data quality for decentralized trials, replacing siloed systems with integrated digital tools, data, and interfaces to accelerate trial execution. Medable connects patients, sites, and clinical trial teams to improve patient access, experience, and outcomes. Medable is a privately held, venture-backed company headquartered in Palo Alto, California.
*American Society of Clinical Oncology, Educational Book, volume 36, “The role of clinical trial participation in cancer research: Barriers, Evidence, and Strategies,” by Joseph M. Unger, PhD, Elise Cook, MD, Eric Tai, MD, and Archie Bleyer, MD (Accessed Here October 2022).
